Global CGRP Inhibitor Market Size is valued at USD 3.3 Bn in 2024 and is predicted to reach USD 8.5 Bn by the year 2034 at a 10.2% CAGR during the forecast period for 2025-2034.
CGRP inhibitors are often used as preventative therapies for constant migraines, offering a new and focused method of treating a disorder that has an enormous adverse effect on the standard of existence for many people globally. Because of its ability to alter the processes of CGRP, an amino acid linked to the development and spread of migraines, CGRP inhibitors are used. Furthermore, more dependable and effective CGRP inhibitors have been developed as a result of advances in neurology and biotechnology that have made it simpler to understand the underlying reasons for migraine.
Additionally, partnerships & agreements between pharmaceutical companies and healthcare providers might increase awareness of CGRP inhibitors and lower their cost and accessibility. This will help this new industry grow and expand overall.
However, CGRP inhibitors face a difficult path to legislative authorization. To prove security, efficacy, and excellence, these drugs must go through a rigorous laboratory and clinical evaluation process. CGRP inhibitor clinical trials are complicated and lengthy, with several patient groups and stages. These investigations are essential for figuring out the safety and effectiveness features of the drugs, even though they frequently need to be completed. Delays may result from problems with recruiting, data collection, and the need for ongoing monitoring. It takes a lot of work to ensure compliance with regulations, and if done poorly, it might lead to more delays. Additional study and a longer approval period might result from any evidence of adverse effects or safety concerns.
Some major key players in the CGRP inhibitor market:
The CGRP inhibitor market is segmented based on treatment, route of administration, and end-user. As per the treatment category, the market is further divided into preventive and acute. The route of administration segment includes oral, nasal, and intravenous. The end-user category, the market is segmented into hospitals, pharmacies, and speciality clinics.
Preventive therapies are expected to hold a major global market share in 2021 in the CGRP inhibitor market because they are increasingly being used in the proactive treatment of diseases like persistent migraines. Patients and healthcare professionals are very interested in preventive therapies since they can lower the frequency and intensity of headaches. Preventive therapies are driving substantial demand as long-term therapeutic advantages become more widely recognized, making this category the main factor of market expansion.
The speciality clinics segment is growing in the CGRP inhibitor market because they are more specialized. They may provide more individualized treatment regimens and more stringent patient monitoring in order to maximize the benefits of CGRP inhibitor medication. Since the need for specialist CGRP Inhibitors accounts for a sizeable portion of income, speciality clinics are anticipated to contribute to the supply and administration of these medications as the need for specialized treatment increases.
The North American CGRP inhibitor market is expected to report the most elevated market share in revenue in the near future. This can be ascribed to its advanced healthcare system, focus on development and research, and quick adoption of cutting-edge cancer therapies. Due to the existence of significant pharmaceutical businesses and a large amount of clinical investigation activity, the United States especially contributes an essential position. In addition, the Europe is expected to grow rapidly in the CGRP inhibitor market because of variables such as an ageing and massive populace, an increase in the prevalence of malignancy, and better healthcare facilities. The availability of affordable treatment alternatives and increased knowledge of cutting-edge cancer medicines are driving market expansion more rapidly.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 3.3 Bn |
|
Revenue Forecast In 2034 |
USD 8.5 Bn |
|
Growth Rate CAGR |
CAGR of 10.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, Route Of Administration, And End-User. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Eli Lilly and Company, Pfizer Inc, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Amgen Inc, Novartis AG, Allergan, Biohaven Pharmaceutical Holding Company Ltd., and Sun Pharmaceutical Industries Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CGRP Inhibitor Market Snapshot
Chapter 4. Global CGRP Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on CGRP Inhibitor Market Industry Trends
4.10. Global CGRP Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. CGRP Inhibitor Market Segmentation 1: By Treatment, Estimates & Trend Analysis
5.1. Market Share By Treatment, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Preventive
5.2.2. Acute
Chapter 6. CGRP Inhibitor Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis
6.1. Market Share By Route of Administration, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source:
6.2.1. Oral
6.2.2. Nasal
6.2.3. Intravenous
Chapter 7. CGRP Inhibitor Market Segmentation 3: By End-User, Estimates & Trend Analysis
7.1. Market Share By End-User, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
7.2.1. Hospitals
7.2.2. Pharmacies
7.2.3. Specialty Clinics
Chapter 8. CGRP Inhibitor Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. Global CGRP Inhibitor Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034
8.2.3. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
8.2.4. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034
8.3. Europe
8.3.1. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034
8.3.3. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
8.3.4. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Southeast Asia
8.4.1.7. Rest of Asia Pacific
8.4.2. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034
8.4.3. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
8.4.4. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034
8.5. Latin America
8.5.1. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034
8.5.3. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
8.5.4. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034
8.6.3. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
8.6.4. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Eli Lilly and Company
9.2.1.1. Business Overview
9.2.1.2. Key Product Type/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Pfizer Inc
9.2.3. Teva Pharmaceutical Industries Ltd
9.2.4. AbbVie Inc.
9.2.5. Amgen Inc
9.2.6. Novartis AG
9.2.7. Allergan
9.2.8. Biohaven Pharmaceutical Holding Company Ltd.
9.2.9. Sun Pharmaceutical Industries Ltd
9.2.10. Lundbeck
9.2.11. AstraZeneca plc
9.2.12. F. HoffmannLa Roche Ltd
9.2.13. Bristol Myers Squibb Company
9.2.14. Other Market Players.
Segmentation of CGRP Inhibitor Market -
CGRP Inhibitor Market By Treatment-
CGRP Inhibitor Market By Route of Administration-
CGRP Inhibitor Market By End-User-
CGRP Inhibitor Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
